Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2016, Article ID 8252605, 11 pages
http://dx.doi.org/10.1155/2016/8252605
Research Article

Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus

1Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
2College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, China
3The Center of Laboratory Medicine, General Hospital of Ningxia Medical University, Yinchuan 750004, China
4Institute of Human Stem Cell Research at General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China

Received 17 January 2016; Accepted 15 February 2016

Academic Editor: Ricard Cervera

Copyright © 2016 Shuhong Chi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Y. Yap and K. N. Lai, “Pathogenesis of renal disease in systemic lupus erythematosus—the role of autoantibodies and lymphocytes subset abnormalities,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 7917–7931, 2015. View at Publisher · View at Google Scholar
  2. G. Moroni, S. Quaglini, A. Radice et al., “The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy,” Journal of Immunology Research, vol. 2015, Article ID 106904, 8 pages, 2015. View at Publisher · View at Google Scholar
  3. P. Eggleton, O. C. Ukoumunne, I. Cottrell et al., “Autoantibodies against C1q as a diagnostic measure of lupus nephritis: systematic review and meta-analysis,” Journal of Clinical & Cellular Immunology, vol. 5, no. 2, article 210, 2014. View at Publisher · View at Google Scholar
  4. B. E. Gilliam, A. K. Ombrello, R. W. Burlingame, P. H. Pepmueller, and T. L. Moore, “Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations,” Seminars in Arthritis and Rheumatism, vol. 41, no. 6, pp. 840–848, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Yaniv, G. Twig, D. B. E.-A. Shor et al., “A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients,” Autoimmunity Reviews, vol. 14, no. 1, pp. 75–79, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Chi, Y. Yu, J. Shi et al., “Antibodies against C1q are a valuable serological marker for identification of systemic lupus erythematosus patients with active lupus nephritis,” Disease Markers, vol. 2015, Article ID 450351, 11 pages, 2015. View at Publisher · View at Google Scholar
  7. F. Q. Wu, Q. Zhao, X. D. Cui, and W. Zhang, “C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus,” Rheumatology International, vol. 31, no. 4, pp. 501–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. X.-W. Yang, Y. Tan, F. Yu, and M.-H. Zhao, “Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis,” Nephrology Dialysis Transplantation, vol. 27, no. 9, pp. 3552–3559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. S. E. M. A. Kader, M. M. A. Elaziz, and D. H. Ahmed, “Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE,” Expert Opinion on Medical Diagnostics, vol. 6, no. 6, pp. 489–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Gargiulo Mde, G. Gomez, M. Khoury et al., “Association between the presence of anti-C1q antibodies and active nephritis in patients with systemic lupus erythematosus,” Medicina (B Aires), vol. 75, no. 1, pp. 23–28, 2015. View at Google Scholar
  11. Y. Yin, X. Wu, G. Shan, and X. Zhang, “Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis,” Lupus, vol. 21, no. 10, pp. 1088–1097, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Bock, I. Heijnen, M. Trendelenburg, and M. Kuwana, “Anti-C1q antibodies as a follow-up marker in SLE patients,” PLoS ONE, vol. 10, no. 4, Article ID e0123572, 2015. View at Publisher · View at Google Scholar
  13. M. Mahler, R. A. Van Schaarenburg, and L. A. Trouw, “Anti-C1q autoantibodies, novel tests, and clinical consequences,” Frontiers in Immunology, vol. 4, no. MAY, Article ID article 117, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Orbai, L. Truedsson, G. Sturfelt et al., “Anti-C1q antibodies in systemic lupus erythematosus,” Lupus, vol. 24, no. 1, pp. 42–49, 2015. View at Publisher · View at Google Scholar
  15. Y. Tan, D. Song, L.-H. Wu, F. Yu, and M.-H. Zhao, “Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis,” BMC Nephrology, vol. 14, no. 1, article 63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, “Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4,” Rheumatology International, vol. 32, no. 8, pp. 2445–2451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Jesus, L. M. Campos, B. L. Liphaus et al., “Anti-C1q, anti-chromatin/nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients,” Revista Brasileira de Reumatologia, vol. 52, no. 6, pp. 976–981, 2012. View at Publisher · View at Google Scholar
  18. V. Živković, A. Stanković, T. Cvetković et al., “Anti-dsDNA, Anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus,” Srpski Arhiv za Celokupno Lekarstvo, vol. 142, no. 7-8, pp. 431–436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Y. H. Yap and K. N. Lai, “Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 365083, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Stypińska and A. Paradowska-Gorycka, “Cytokines and MicroRNAs as candidate biomarkers for systemic lupus erythematosus,” International Journal of Molecular Sciences, vol. 16, no. 10, pp. 24194–24218, 2015. View at Publisher · View at Google Scholar
  21. T. A. Gottschalk, E. Tsantikos, and M. L. Hibbs, “Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus,” Frontiers in Immunology, vol. 6, article 550, 2015. View at Publisher · View at Google Scholar
  22. E. Hoe, F. C. McKay, S. D. Schibeci et al., “Functionally significant differences in expression of disease-associated IL-7 receptor α haplotypes in CD4 T cells and dendritic cells,” The Journal of Immunology, vol. 184, no. 5, pp. 2512–2517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. S. Kim, B. A. Cho, J. H. Sim et al., “IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus,” Rheumatology, vol. 51, no. 9, pp. 1587–1594, 2012. View at Publisher · View at Google Scholar
  24. W. Lundstrom, S. Highfill, S. T. Walsh et al., “Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 19, pp. E1761–E1770, 2013. View at Publisher · View at Google Scholar
  25. X.-S. Wang, B.-Z. Li, L.-F. Hu et al., “Perspectives of the relationship between IL-7 and autoimmune diseases,” Clinical Rheumatology, vol. 32, no. 12, pp. 1703–1709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Badot, R. K. M. A. C. Luijten, J. A. Van Roon et al., “Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 453–456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Dooms, “Interleukin-7: fuel for the autoimmune attack,” Journal of Autoimmunity, vol. 45, pp. 40–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. T. Tan, E. Dudl, E. LeRoy et al., “IL-7 is critical for homeostatic proliferation and survival of naïve T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8732–8737, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-H. Park, Q. Yu, B. Erman et al., “Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival,” Immunity, vol. 21, no. 2, pp. 289–302, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Guimond, R. G. Veenstra, D. J. Grindler et al., “Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells,” Nature Immunology, vol. 10, no. 2, pp. 149–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Badot, P. Durez, B. J. Van den Eynde, A. Nzeusseu-Toukap, F. A. Houssiau, and B. R. Lauwerys, “Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines,” Journal of Cellular and Molecular Medicine, vol. 15, no. 11, pp. 2335–2342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Haas, M. Korporal, A. Schwarz, B. Balint, and B. Wildemann, “The interleukin-7 receptor α chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis,” European Journal of Immunology, vol. 41, no. 3, pp. 845–853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Poiret, L. Rane, M. Remberger et al., “Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults,” BMC Immunology, vol. 15, no. 1, article 25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. X.-S. Wang, P.-F. Wen, M. Zhang et al., “Interleukin-7 receptor single nucleotide polymorphism rs6897932 (C/T) and the susceptibility to systemic lupus erythematosus,” Inflammation, vol. 37, no. 2, pp. 615–620, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. B. R. Lauwerys, S. N. Husson, A. L. Maudoux, V. Badot, and F. A. Houssiau, “sIL7R concentrations in the serum reflect disease activity in the lupus kidney,” Lupus Science & Medicine, vol. 1, no. 1, Article ID e000036, 2014. View at Publisher · View at Google Scholar
  36. E. Akhter, R. W. Burlingame, A. L. Seaman, L. Magder, and M. Petri, “Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers,” Lupus, vol. 20, no. 12, pp. 1267–1274, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Marto, M. L. Bertolaccini, E. Calabuig, G. R. V. Hughes, and M. A. Khamashta, “Anti-C1q antibodies in nephritis: Correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 444–448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. E. M. Tan, A. S. Cohen, J. F. Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythrematosus,” Arthritis and Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Petri, N. Kasitanon, S.-S. Lee et al., “Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index,” Arthritis and Rheumatism, vol. 58, no. 6, pp. 1784–1788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. D. D. Gladman, D. Ibañez, and M. B. Urowltz, “Systemic lupus erythematosus disease activity index 2000,” Journal of Rheumatology, vol. 29, no. 2, pp. 288–291, 2002. View at Google Scholar · View at Scopus
  41. Z. Touma, D. D. Gladman, A. MacKinnon et al., “Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website,” Journal of Rheumatology, vol. 40, no. 1, pp. 34–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Alba, L. Bento, M. J. Cuadrado et al., “Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis,” Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 556–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Bootsma, P. Spronk, R. Derksen et al., “Prevention of relapses in systemic lupus erythematosus,” Lancet, vol. 345, no. 8965, pp. 1595–1599, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. M. C. Pickering and M. Botto, “Are anti-C1q antibodies different from other SLE autoantibodies?” Nature Reviews Rheumatology, vol. 6, no. 8, pp. 490–493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Matrat, C. Veysseyre-Balter, P. Trolliet et al., “Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares,” Lupus, vol. 20, no. 1, pp. 28–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. G. Moura, I. Lima, L. Barbosa et al., “Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus,” Journal of Clinical Laboratory Analysis, vol. 23, no. 1, pp. 19–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. A. Trouw and M. R. Daha, “Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis,” Expert Opinion on Biological Therapy, vol. 5, no. 2, pp. 243–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Thanei, D. Vanhecke, and M. Trendelenburg, “Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways,” Clinical Immunology, vol. 160, no. 2, pp. 180–187, 2015. View at Publisher · View at Google Scholar
  49. V. Badot, C. Galant, A. N. Toukap et al., “Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 11, no. 2, article R57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Nzeusseu Toukap, C. Galant, I. Theate et al., “Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 56, no. 5, pp. 1579–1588, 2007. View at Publisher · View at Google Scholar · View at Scopus